News
First global approval for Daiichi Sankyo's Dato-DXd
Daiichi Sankyo has claimed approval in Japan, its home market, for …
20075 items found
Digital
Digital biomarkers: Redefining respiratory care
Respiratory diseases, common examples of which include asthma and …
News
Opdivo's subcutaneous PD-1 inhibitor cleared in US
Bristol Myers Squibb's Opdivo has been approved in a subcutaneous …
R&D
Diversity in STEM in 2024: A reflection and a path forward
In recent years, the fields of Science, Technology, Engineering, and …
Sales & Marketing
News
Amid BIOSECURE Act speculation, WuXi AppTec sells unit
China's WuXi AppTec has agreed to sell a business unit serving the …
News
PhRMA said to be donating $1m to Trump inauguration
The Pharmaceutical Research and Manufacturers of America (PhRMA) …
Digital
Generative AI in pharma: Moving beyond hype and into widespread adoption
Generative AI (GenAI) has rapidly pushed its way to the forefront of …
R&D
Where do we stand with clinical trial digitalisation?
Digitalisation is happening all around us, including in tech-enabled …
News
Daiichi and AZ pull Dato-DXd filing in Europe too
AstraZeneca and Daiichi Sankyo confirmed today that they have decided …
News
FDA approves flurry of drugs ahead of holiday season
The FDA has followed its usual procedure of wrapping up a series of …
Oncology
Transforming autoimmune disease therapy: Post-ACR 2024 perspectives on cell therapies
The 2024 American College of Rheumatology (ACR) annual meeting …
News
First global approval for Daiichi Sankyo's Dato-DXd
Daiichi Sankyo has claimed its first approval, in Japan, for TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan.
Sales & Marketing
Sponsored
Health Trends 2025: Reimagining What's Possible
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
Digital
Deep Dive: AI 2024
In this issue, we delve into the transformative impact of AI on healthcare and pharma, featuring insights on key AI trends from the floor of Frontiers Health, the ongoing battle against drift, and
Spotlight on
World Without Disease initiative: 2024 update
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year
R&D
Precision medicine, NGS, and the quantum leap in biomarkers
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company
Digital
Sponsored
How to deal with fragmented data - A $12.9 million challenge
In the age of AI, large data sets – like the treasure trove of customer data most biopharma companies are sitting on – are an invaluable asset.
R&D
Partner Content
hubXchange returns with its latest series of roundtables!
hubXchange invites you to participate in its highly-anticipated San Diego Series 2025, a series of focused, high-level roundtable events designed to address key challenges and innovations across th
R&D
Partner Content
Advance Best-In-Class Treatment Across CNS, Emergency Use Tr...
With nasal delivery systems offering faster absorption and non-invasive administration, they are becoming a cornerstone of modern therapeutics.
